Key result
FDG-PET correctly differentiated benign from malignant adrenal lesions, with a significantly higher mean tumor-to-background ratio for malignant (7.4) versus benign (0.8) lesions (P<.001).
Why the study?
Does FDG-PET accurately differentiate benign from malignant adrenal masses in patients with cancer?
Observational (n=20)
Does FDG-PET accurately differentiate benign from malignant adrenal masses in patients with cancer?
Absolute Event Rate: 7.4% vs 0.8%
p-value: p=< .001
FDG-PET accurately differentiates benign from malignant adrenal masses in patients with cancer, demonstrating significantly higher tumor-to-background ratios in malignant lesions.
FDG-PET correctly differentiated benign from malignant adrenal lesions; leaves open need for larger prospective validation before clinical adoption.
PURPOSE: To evaluate the ability of positron emission tomography (PET) to characterize adrenal masses in patients with cancer. MATERIALS AND METHODS: Twenty-four adrenal masses (size range, 1.5-10.0 cm [mean, 2.8 cm]) in 20 patients (13 men and seven women) with cancer (lung [n = 10], colon [n = 3], lymphoma [n = 3], miscellaneous [n = 4]) were evaluated. PET was performed in fasting patients 45 minutes after infusion of 5-10 mCi (185-370 MBq) of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG). PET images were correlated with findings at computed tomography (CT), surgery, and/or percutaneous biopsy. RESULTS: Fourteen adrenal masses were proved malignant at surgery (n = 4), biopsy (n = 7), or follow-up (n = 3). Ten lesions were proved benign at biopsy (n = 4) or follow-up CT (n = 6). PET helped correct differentiation of benign from malignant adrenal lesions in all patients. A statistically significant difference (P < .001) was seen between mean tumor-to-background ratios for malignant (mean, 7.4; range, 2.9-16.6; median, 6.9) versus benign (mean, 0.8; range, 0.2-1.2; median, 0.6) adrenal lesions. CONCLUSION: PET helped correct differentiation of benign from malignant adrenal lesions.
No takes yet. Share an insight, caveat, or question.
Boland et al. (1995) conducted an observational in Cancer with indeterminate adrenal mass (n=20). FDG-PET vs. Benign lesions (reference standard: CT, surgery, biopsy) was evaluated on Tumor-to-background ratio (p=< .001). FDG-PET correctly differentiated benign from malignant adrenal lesions, with a significantly higher mean tumor-to-background ratio for malignant (7.4) versus benign (0.8) lesions (P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: